[April 18, 2018] |
|
Appili Therapeutics to Present at 2018 Bloom Burton & Co. Healthcare Investor Conference
Appili Therapeutics Inc. (the "Company" or "Appili"), a
biopharmaceutical company focused on anti-infective drug development,
announced today that it will participate in this year's annual Bloom
Burton & Co. Healthcare Investor Conference. The conference takes place
May 2-3, 2018 in Toronto, Canada.
Appili's Chief
Executive Officer Kevin Sullivan will present a corporate overview
and update on the Company's active pipeline and business development
programs.
Presentation details are as follows: Date: Wednesday, May 2,
2018 Time: 2:00 p.m. ET Location: Sheraton
Centre Hotel Toronto, 123 Queen Street, Toronto, Ontario, M5H 2M9
Investors interested in arranging a meeting with Mr. Sullivan during
this conference should contact Bloom Burton & Co.'s conference
coordinator.
About the Conference he Bloom Burton & Co. Healthcare
Investor Conference brings together U.S., Canadian and international
investors who are interested in the latest developments in the Canadian
healthcare sector. Attendees will have an opportunity to obtain
corporate updates from the premier Canadian publicly traded and private
companies through presentations and private meetings.
About Appili Therapeutics Appili Therapeutics, Inc., was
founded to advance the global fight against infectious disease by
matching clearly-defined patient needs with drug development programs
that provide solutions to existing challenges patients, doctors and
society face in this challenging disease space. Balancing near-to-market
product candidates with higher-risk but potentially transformative
early-stage programs, Appili's growing pipeline includes assets being
developed by Appili as well as an active licensing program. ATI-1501
employs Appili's proprietary, taste-masked, oral-suspension technology
with metronidazole for the growing number of pediatric and elderly
patients with difficulty swallowing. ATI-1503 is a drug discovery
program aimed at generating negamycin analogue candidates, a novel class
of antibiotics with broad-spectrum activity against Gram-negative
bacteria. Via an in-licensing program, Appili acquired the rights to
ATI-1701, a vaccine for tularemia, removing risk from a weaponized
bioterrorism pathogen. Headquartered in Halifax, Nova Scotia, with
offices in Mississauga, Ontario, Appili is pursuing worldwide
opportunities in collaboration with science and industry commercial
partners, governments and government agencies. For more information,
visit www.AppiliTherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180418005211/en/
[ Back To TMCnet.com's Homepage ]
|